$8.08
-0.27-3.23%
At close: -
$8.69
0.617.55%
After Hours: Apr 25, 9:27 AM EDT
Comments
Loading...
Corbus Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:CRBP | Benzinga
Corbus Pharmaceuticals Holdings Inc has a consensus price target of $60.89 based on the ratings of 10 analysts. The high is $88 issued by Oppenheimer on August 7, 2024. The low is $35 issued by Piper Sandler on December 2, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Jefferies, and HC Wainwright & Co. on March 12, 2025, March 11, 2025, and February 18, 2025, respectively. With an average price target of $59.33 between HC Wainwright & Co., Jefferies, and HC Wainwright & Co., there's an implied 582.78% upside for Corbus Pharmaceuticals Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Jefferies
HC Wainwright & Co.
Piper Sandler
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Corbus Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | Buy Now | 475.37% | HC Wainwright & Co. | Andres Maldonado43% | $75 → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/11/2025 | Buy Now | 509.9% | Jefferies | Maury Raycroft32% | $70 → $53 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | William Blair | Andy Hsieh21% | — | Initiates | → Outperform | Get Alert |
| 02/18/2025 | Buy Now | 763.06% | HC Wainwright & Co. | Andrew Fein56% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | 763.06% | HC Wainwright & Co. | Andrew Fein56% | $80 → $75 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | 302.76% | Piper Sandler | Biren Amin41% | → $35 | Initiates | → Overweight | Get Alert |
| 09/23/2024 | Buy Now | 820.6% | HC Wainwright & Co. | Andrew Fein56% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2024 | Buy Now | 360.3% | B. Riley Securities | Kalpit Patel41% | $85 → $40 | Maintains | Buy | Get Alert |
| 09/20/2024 | Buy Now | 486.88% | Wedbush | Robert Driscoll44% | $85 → $51 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 751.55% | Mizuho | Graig Suvannavejh50% | $74 → $74 | Reiterates | Outperform → Outperform | Get Alert |
| 09/20/2024 | Buy Now | 843.61% | RBC Capital | Brian Abrahams49% | $82 → $82 | Reiterates | Outperform → Outperform | Get Alert |
| 08/28/2024 | Buy Now | 843.61% | RBC Capital | Brian Abrahams49% | $82 → $82 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | 843.61% | RBC Capital | Brian Abrahams49% | $82 → $82 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | 912.66% | Oppenheimer | Jeff Jones33% | $80 → $88 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 820.6% | HC Wainwright & Co. | Andrew Fein56% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 820.6% | HC Wainwright & Co. | Andrew Fein56% | → $80 | Reinstates | → Buy | Get Alert |
| 07/10/2024 | Buy Now | 820.6% | Oppenheimer | Jeff Jones33% | $80 → $80 | Reiterates | Outperform → Outperform | Get Alert |
| 06/26/2024 | Buy Now | 878.14% | B. Riley Securities | Kalpit Patel41% | → $85 | Initiates | → Buy | Get Alert |
| 06/11/2024 | Buy Now | 843.61% | RBC Capital | Brian Abrahams49% | $77 → $82 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | 820.6% | Oppenheimer | Jeff Jones33% | $60 → $80 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | 786.08% | RBC Capital | Brian Abrahams49% | → $77 | Initiates | → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 590.45% | Oppenheimer | Jeff Jones33% | $58 → $60 | Maintains | Outperform | Get Alert |
| 03/13/2024 | Buy Now | 567.43% | Oppenheimer | Jeff Jones33% | $51 → $58 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | Buy Now | 429.34% | Jefferies | Maury Raycroft32% | $4 → $46 | Upgrade | Hold → Buy | Get Alert |
| 01/29/2024 | Buy Now | 486.88% | Oppenheimer | Jeff Jones33% | $20 → $51 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 153.16% | Oppenheimer | Jeff Jones33% | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/10/2023 | Buy Now | 153.16% | Oppenheimer | Jeff Jones33% | → $22 | Upgrade | Perform → Outperform | Get Alert |
| 03/08/2023 | Buy Now | -65.48% | HC Wainwright & Co. | Andrew Fein56% | → $3 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | -65.48% | HC Wainwright & Co. | Andrew Fein56% | → $3 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Corbus Pharmaceuticals (CRBP) stock?
The latest price target for Corbus Pharmaceuticals (NASDAQ:CRBP) was reported by HC Wainwright & Co. on March 12, 2025. The analyst firm set a price target for $50.00 expecting CRBP to rise to within 12 months (a possible 475.37% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ:CRBP) was provided by HC Wainwright & Co., and Corbus Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Corbus Pharmaceuticals (CRBP)?
The last upgrade for Corbus Pharmaceuticals Holdings Inc happened on March 6, 2024 when Jefferies raised their price target to $46. Jefferies previously had a hold for Corbus Pharmaceuticals Holdings Inc.
When was the last downgrade for Corbus Pharmaceuticals (CRBP)?
There is no last downgrade for Corbus Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on March 12, 2025 so you should expect the next rating to be made available sometime around March 12, 2026.
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $75.00 to $50.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $8.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
